The professional's guide to product selection
Tavegil (clemastine) is an H1-recptor antagonist. It belongs to the benzhydryl ether group of antihistamines. Tavegil inhibits selectively the histamine receptors of the H1 type and reduces capillary permeability. It exerts a potent antihistaminic and antipruritic effect with a fast onset and long duration of action up to 12 hours
Tetralysal contains 408mg of lymecycline, equivalent to 300mg tetracycline base. Tetracyclines provide bacteriostatic action at the available plasma and tissue concentrations and are effective against intracellular and extracellular organisms. Their mechanism of action is based on the inhibition of ribosomal protein synthesis. Tetracyclines block the access of the bacterial aminoacyl-tRNA to the mRNA-ribosome complex by binding to the 30S subunit of the ribosome, thus preventing the addition of amino acids to the growing peptide chain in protein synthesis. When given at therapeutically attainable concentrations, their toxic effect is limited to the bacterial cells. The exact mechanisms by which tetracyclines reduce lesions of acne vulgaris have not been fully elucidated, however, the effect appears to result in part from antibacterial activity. Following oral administration, the drugs inhibit the growth of susceptible organisms (mainly Propionibacterium acnes) on the surface of the skin and reduce the concentration of free fatty acids in sebum. The reduction in free fatty acids in sebum may be an indirect result of the inhibition of lipase-producing organisms which convert triglycerides into free fatty acids or maybe a direct result of interference with lipase production in these organisms. Free fatty acids are comedogenic, and are believed to be a possible cause of the inflammatory lesions, e.g. papules, pustules, nodules, cysts, or acne. However, other mechanisms also appear to be involved because clinical improvement of acne vulgaris with oral tetracycline therapy does not necessarily correspond with a reduction in the bacterial flora of the skin or a decrease in the free fatty acid content of sebum
An emollient containing 30% emulsifying wax and 30% yellow soft paraffin
A subcutaneous injection for plaque psoriasis containing the active ingredient tildrakizumab, which acts on cytokine IL-23.
Specifically designed for sensitive, intolerant and reactive skin, containing a range of high tolerance products and formulated with minimum ingredients to limit the risks of allergies. Clinically proven to make your skin less sensitive, while providing long-last hydration.
Tralokinumab is a biologic monoclonal antibody that targets specific proteins or receptors in the body, to regulate the immune response or interfere with disease processes. The liquid solution is injected subcutaneously with a pre-filled syringe to limit the overreaction of the immune system, dampening down inflammation and reducing itch.
Gel combination therapy of clindamycin and tretinoin. Clindamycin is a semisynthetic derivative of the parent compound lincomycin that is produced by Streptomyces lincolnensis and is predominantly bacteriostatic. Topical tretinoin has both comedolytic and anti-inflammatory effects. Tretinoin decreases cohesiveness of follicular epithelial cells resulting in decreased microcomedone formation. Additionally, tretinoin stimulates mitotic activity and increased turnover of follicular epithelial cells, causing extrusion of the comedones.
An innovative Photodynamic Therapy (PDT) Machine featuring normal PDT, pulsed PDT for reduced treatment pain, compact daylight PDT when effective daylight is unavailable. It is used with a licenced photosensitiser, such as Metvix from Galderma or Ameluz from Biofrontera
A water-miscible cream containing clobetasone 17-butyrate 0.05% w/w, oxytetracycline 3.0% w/w as calcium oxytetracycline and nystatin 100,000 units per gram.